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Abstract 
Enzyme-linked immunosorbent assay (ELISA) is often used to test bovine 
leukemia virus (BLV) infection. However, commercially available kits test in 
South America detect only antibodies against the gp51 protein. With the aim 
to improve the sensitivity of the test, we developed here a two-step indirect 
dual ELISA test that included both proteins p24 and gp51, expressed and 
produced in E. coli and baculovirus expression system respectively. Two hun-
dred ten BLV sera, stated as double positive or double negative by the combi-
nation of commercial agar gel immunodiffusion (AGID) assay and a gp51- 
ELISA test, were tested with our in house dual rp24/rgp51 ELISA. Firstly, we 
checked the purified, optimized and standardized proteins as antigen by the 
checkerboard technique, and set up our in house ELISA test. The concordance 
correlation coefficient (CCC) and coefficient of variation (CV) intraplate re-
peatability levels were within the values established by the international stan-
dards. The statistical analysis demonstrated the value of sera correctly ranked 
highest (93.48%), and for 0.3 cutoff, the sensitivity was 95.65% and the speci-
ficity 91.30%. In conclusion, the rp24/rgp51 ELISA developed and standar-
dized here demonstrated to have good analytical characteristics to be consi-
dered for screening of BLV. 
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1. Introduction 
The bovine leukemia virus (BLV) is the causative agent of Enzootic Bovine Leu-
kosis (EBL), a lymphoproliferative type disease that affects B cells, and the pro-
virus is integrated into the genome, transforming infected animals in Lifetime 
carriers [1]. Given the multiple transmission routes, both natural and iatrogenic 
and the minimum volumes of peripheral blood required to transmit the virus, 
this disease has a high potential for disease transmission [2] [3].  
The economic impact of this disease lies not only in direct losses for confisca-
tion at the slaughterhouse, but also the associated carrier status of the animal, 
with an important decrease in animal productivity [4]; that also include the costs 
of veterinary services, diagnosis and treatment of the disease, as well as the costs 
of early animal replacement [5]. 
The Bovine leukemia virus (BLV) is an exogenous B-lymphotropic retrovirus 
that naturally provokes B-lymphoproliferative disorders in cattle and can be 
used to induce a related B-cell-associated pathology in experimentally infected 
sheep [6]. Structural proteins p24 and gp51 are potent immunogens and the an-
tibody production can be detected in most of the animals infected with VLB. In 
experimentally infected animals anti-gp51 antibodies seem to be the first to ap-
pear with titres consistently higher than anti-p24 antibodies [7] [8] [9]. Other 
authors reports that high sensitivity tests are able to detect anti-p24 antibodies 
before the appearance of anti-gp51 antibodies; and the anti-p24 antibodies could 
be an equal or greater degree than anti-gp51 [3] [10]. The immunoglobulin iso-
type in the immune response varies according to the stages of LEB disease, in 
asymptomatic animals IgM and IgG1 anti p24 and gp51were detected, whereas 
the detection of IgA occurs in animals with lymphoma [11]. 
The most frequently used serological tests to detect VLB infection are agar gel 
immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA). 
The AGID, that mainly detects anti-gp51 antibodies [9], is a test with high speci-
ficity, low cost, quick and easy to perform, but with some main disadvantages 
like low sensitivity, time consuming for reading and subjective interpretation of 
test results and is unable to be performed with milk samples [12]. At the present, 
the detection of specific antibodies based on the recognition of crude antigens by 
AGID or ELISA requires mass production of the virus from persistently infected 
FLK cell lines cultures. The use of Escherichia coli or baculovirus expression 
systems to produce recombinant antigen(s) would be greatly beneficial in im-
proving standardization of the tests and reducing their production cost. 
Enzyme-linked immunosorbent assay (ELISA) tests using VLB antigens have 
already been reported [12] [13], but compared to the current serological tests, 
none of these recombinant antigens has allowed detection of all serologically 
positive individuals. The aim of this study was to develop an indirect dual ELISA 
test that included both recombinant proteins p24 and gp51 directly absorb to the 
96-well plate, to be used in Argentina and other countries of South America. The 
use and evaluation of the two recombinant antigens could be a strategy to im-
prove the sensitivity of recombinant antigen-based tests for the serodiagnosis of 
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LEB. 
2. Materials and Methods 
2.1. Sera Samples 
A total of 283 serum samples, collected from naturally infected adult cows from 
different herds, were obtained from the serum bank of the Virology Laboratory 
of the Veterinary Faculty of University of La Plata, Argentina. The sera samples 
were tested for the presence of BLV specific antibodies by AGID and a commer-
cial indirect ELISA test. International reference serum sample E4 (Veterinary 
Laboratories Agency. New Haw, Adelestope Surrey. UK) was used as control.  
2.2. Recombinant Antigens Production 
2.2.1. Expression and Purification of Recombinant p24 Antigen in  
Bacterial Cell 
The complete coding region for the p24 gene of the BLV was amplified by PCR 
using the FLK (fetal lamb kidney) BLV infected cell line as a template. The pri-
mers used carried a Bam HI restriction sites for the forward primer (5’-GGC 
GGA TCC ATG CCA ATC ATA TCT GAA-3’) and a Hind III site for reverse 
primer (5’-GGC AAG CTT TAG AGA AGT GCA GGC TGT-3’). The primers 
were designed based on the genomic sequence deposited in GenBank under ac-
cession number K02120.1. PCR was carried out by denaturing at 94˚C for 2 mi-
nutes, 30 cycles of: annealing at 50˚C for 45 seconds, extension at 72˚C for 2 
minutes, followed by a final extension period at 72˚C for 10 minutes. The PCR 
product was digested with both BamHI and HindIII, cloned into the pQE-30 
expression vector (QIAGEN)) and the transformation of competent M15 
[pREP4] E. coli cells (QIAGEN) were performed according to the manufactur-
er’s instructions. To determine the presence of the recombinant plasmid, a PCR 
was performed and the product was used for confirm the insertion of the gene in 
frame. The absence of mutations in the p24 gene was confirmed by plasmids se-
quencing using M13 forward and reverse primers. The sequencing results were 
analyzed by comparing with databases and using the basic local alignment 
search tool (BLAST) software. 
The selected E. coli p24/clones were inoculated into LB medium contained 0.1 
mM of IPTG (isopropyl-bD-thiogalactopyranoside) for induction; the medium 
was supplemented with ampicillin (100 mg/ml) and kanamycin (25 µg/ml). The 
purification of the recombinant protein was performed in batch, the buffer used 
(50 mM NaH2PO4 and 500 mM NaCl), was the same all along the protocol. The 
cells were pelleted and resuspended in lysis buffer pH7, lysozyme (1 mg/ml) was 
added and incubate at 37˚C for 30 min. The lysis was completed by few rounds 
of sonication. The presence of the protein was analyzed by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 12% polyacryla-
mide gel and the antigenicity of the protein by Western blot analysis according 
to the standard proceeding, using E4 control sera (Veterinary Laboratories 
Agency. New Haw, Adelestope Surrey. UK), a commercial BLV p24 monoclonal 
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antibody (VMRD Inc., WA USA) and a pool of negative control serums. 
The recombinant protein were purified from the supernatant lysate using 
Ni-NTA (QIAGEN, USA) and eluted off the resin by buffer pH4.The concentra-
tion of the recombinant protein was determined by a quantitative Coomassie 
blue-stained gel using bovine serum albumin as the standard.  
2.2.2. Expression and Purification of Recombinant gp51 Antigen in  
Insect Cell 
The complete coding region for the gp51 gene of the BLV was amplified by PCR 
using the FLK (fetal lamb kidney) BLV infected cell line as a template and the 
following set of primers: forward 5’-CAC CAT GCC TAA AGA ACG A-3’, and 
reverse: 5’-CCG GGT AGG AGG GGC GGA-3’. The primers were designed 
based on the genomic sequence deposited in GenBank under accession number: 
K02120.1. PCR was carried out by denaturing at 94˚C for 2 minutes, 30 cycles of: 
annealing at 55˚C for 45 seconds, extension at 72˚C for 2 minutes, followed by a 
final extension period at 72˚C for 10 minutes. A CACC sequence (underlined) 
was introduced in the forward primer for directional cloning into the entry vec-
tor (pENTR/D-TOPO—BaculoDirect TM GST Gateway, Invitrogen. USA), fol-
lowing the manufacturer’s instructions. 
The rgp51/pENTR/D-TOPO cloning vector was amplified in TOP10 E. coli 
cells and the absence of mutations in the gp51 gene was confirmed by plasmids 
sequencing using M13 forward and reverse primers. The sequencing results were 
analyzed by comparing with databases and using the basic local alignment 
search tool (BLAST) software. Construction of the Recombinant baculovirus was 
performed following the manufacturer’s instructions of the BaculoDirect™ GST 
Gateway®. System (Invitrogen, UK). Briefly, to obtain the recombinant baculo-
virus, the LR reaction was performed incubating at room temperature the puri-
fied entry vector rgp51/pENTR/D-TOPO with baculovirus linear DNA. The re-
combinant baculovirus directly transfected Sf9 cells in presence of Cellfectin II 
Reagent® (Invitrogen, UK) and Ganciclovir for the recombinant baculovirus se-
lection. Recombinant viruses were purified by plaque assay and screened for the 
expression of recombinant gp51 by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and the specificity was analyzed by Western blot analysis according 
to the standard proceeding, using E4 control sera (Veterinary Laboratories 
Agency. New Haw, Adelestope Surrey. UK), a commercial BLV gp51 monoclon-
al antibody (VMRD Inc., WA USA) and a pool of negative control serums. For 
the production of recombinant gp51, approximately 2 × 106 Sf9 cells were in-
fected with the recombinant virus at a multiplicity of infection of 5, and then 
cultured at 27˚C for 3 days. After culture centrifugation, the cells were harvest 
and resuspended in lysis buffer pH7 with 0.3% SDS (Sodium Dodecyl Sulfate), 
and 1% 2B mercaptoetanol. The complete celllysate was obtained by syringe 
passage consisting of 10 passes with 25-gauge needle followed by 10 passages 
through 27-gauge needle. The purification of the recombinant protein from the 
supernatant lysate was performed as explained above using Ni-NTA (QIAGEN, 
USA).  
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2.3. AGID and Commercial gp51-ELISA Tests 
The AGID test, produced by Universidad de LaPlata, Argentina (UNLP-AGID) 
and a commercial indirect ELISA test kit (VMRD Inc., USA) that detect antibo-
dies against BLV gp51 protein, were used according to the manufacturer’s rec-
ommendations. Both tests were used as standard of comparison against our in 
house ELISA to detect specific BLV antibodies. 
2.4. In House rp24/rgp51 ELISA Procedure 
Two checkerboard tests (CBT) was performed, one for each individual recom-
binant protein (rp24 and rgp51) and the third with a mix of the two proteins. 
Foreach individual recombinant protein CBT, an appropriate ranges of serum 
and conjugate dilutions were identified by preliminary testing to determine the 
optimal dilution of the conjugate (1/2500) and the serum (1/25, 1/50 and 1/100), 
using the following range of proteins concentration (10 to 0.25 ug/ml). The best 
binding ratio was chosen to select the best concentration of the reagents for our 
test. The third CBT was performed with the same serum dilutions as before and 
a mix of the two proteins at different concentrations. Mix 1 (250 ng per well of 
rp24 and 50 ng per well of rgp51), and mix 2 (250 ng per well of rp24 and 25 ng 
per well of rgp51).  
Once the optimal working concentrations for all reagents were determined by 
CBT, we proceeded to perform our rp24/rgp51 ELISA. NuncPolysorp F plates 
were coated overnight at 4˚C with 250 ng/well of rp24 and 25 ng/well of rgp51 
contained in 100 ul of 0.05 mol/l carbonate buffer (pH 9.6). The antigen-coated 
plate was washed three times with PBST (0.01 mol/l phosphate-buffered saline, 
pH 7.4, 0.05% Tween 20) and blocked with PBST containing 1 % (W/V) skim 
milk at 37˚C for 1 h. After washing, 100 ul of the diluted sera panel was added, 
and then incubated at 37˚C for 1 h. The assay was performed using 3 different 
sera dilutions: 1/100, 1/50 and 1/25. After washing, 100 ul of goat anti-bovine 
HRP-IgG antibodies (1:2500) was added and incubated at 37˚C for 1 h. The 
plates were washed three times and then incubated with 100 ul of 30 mg of 2,2 
0-azino-bis-(3-benzthiazoline-6-sulfonic acid) (ABTS) (KPL, Inc.) substrate in 
100mM phosphate-citrate buffer pH 4.0 and 3 ul of 30% H2O, for 40 min at 
room temperature. The optical density (OD) of each well was read at 405 nm 
using a microplate reader (Bio-Rad). Duplicate positive and negative control se-
ra were included in each plate. 
The checkerboard results are assessed by determine the Binding Ratio (BR) 
[14]. 
2.5. Statistical Analysis 
The repeatability within and between plates was analyzed by the reproducibility 
index called the concordance correlation coefficient (CCC) and coefficient of 
variation (CV) [14] [15] [16]. The following formula was used to normalize de 
ELISA results: ODN = OD-Nt/Pst-Nt, where OD is the absorbance value of the 
sample, Pst and Nt are the mean absorbance values of the positive and negative 
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controls on each plate, respectively [15]. 
Calculations to determine test sensitivity and specificity were carried out by 
Stata SE 11 program (Stata Corporation, College Station, Texas, USA) and TG- 
ROC program (Two Graphic Receiver Operating Characteristic). For cutoff cal-
culation the correct classification parameter was used [17].  
3. Results 
3.1. Expression, Purification and Characterization of rp24 in  
E. coli 
The PCR amplification assay generated a unique fragment with the expected 
molecular level (642 bp) and visible on agarose gel under ultraviolet light 
(Figure 1(a)). After cloning of the PCR product to the pQE-30 expression vec-
torthe present of the gene was confirmed by PCR and the purified selected plas-
mid, contained the p24 gene in frame, was sequenced. The sequence analyzed by 
comparing with databases from BLV reference strains showed a 99% of nucleo-
tide identity with BLV cell-line FLK-BLV subclone pBLV913 (GenBankID: 
EF600696.1) and 98% of nucleotide identity con BLV (GenBankID: K02120.1) 
[18]. 
The analysis by SDS PAGE of the Denatured lysate of induced E. coli M15 
(pREP4) showed by Coomassie blue staining the presence of the p24 recombi-
nant protein with the predicted size (24 kDa) corresponding to the molecular 
weight to the fusion protein contained N-terminally His-tag (Figure 1(b)). The 
authenticity of the recombinant protein was confirmed by Western blot analysis 
using the E4 control positive serum (Veterinary Laboratories Agency. New Haw, 
Adelestope Surrey. UK), a commercial monoclonal anti-p24 antibody (VMRD 
Inc., WA USA) and a pool of negative control serum from BLV non-infected 
cow (Figure 2). 
The expressed rp24 protein was subsequently purified using Ni-NTA affinity  
 
 
(a)                                       (b) 
Figure 1. (a) Agarose gel electrophoresis of PCR product. 1: DNA ladder; 2: Amplified 
642 bp PCR product. (b) SDS-PAGE analysis of recombinant p24 protein expressed in E. 
coli. 1: Lysate from cells expressing the rp24 protein; 2: Prestained molecular weight 
marker; 3: Lysate from non-expressing cells. 
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Figure 2. Western Blot analysis of recombinant 
p24 protein expressed in E. coli. 1: Prestained 
molecular weight marker; 2: Monoclonal anti- 
p24 antibody; 3: Pool of negative control serum 
from BLV non-infected cow; 4: Polyclonal E4 
control positive sera. 
 
chromatography by pH elution methods. For yield optimization, several induc-
tion parameters were tested, and the highest yield, 5.6 mg per liter culture, was 
achieved following induction with 0.6 mM IPTG (Isopropyl β-D-1-thiogalacto- 
pyranoside) for 18 h at 25˚C.  
3.2. Expression, Purification and Characterization of rgp51 in  
Baculovirus 
The PCR amplification assay generated a unique fragment with the expected 
molecular level (894 bp) and visible on agarose gel under ultraviolet light 
(Figure 3(a)). A consensus Gateway entry clone was used to produce a baculo-
virus (Acgp51) encoding a C-terminally 6X His-tagged form of the full-length 
gp51 protein under the transcriptional control of the polyhedrin promoter. After 
confirming fragment insertion and orientation by PCR, the purified selected 
plasmid was automated sequenced and the sequence analyzed by comparing 
with databases from BLV reference strains: 99% of nucleotide identity with BLV 
cell-line FLK-BLV subclone pBLV913 (GenBankID: EF600696.1) and 99% of 
nucleotide identity con BLV (GenBankID: K02120.1) [18].  
Acgp51-infected Sf9 cell extracts analyzed by SDS-PAGE showed the presence 
of a very strong protein band of approximately 34 kDa, which was absent in 
mock-infected cell extracts (Figure 3(b)). Recombinant gp51 protein was puri-
fied by Ni2+ affinity purification procedure by pH elution methods. The concen-
tration of the protein was determined with a commercial kit (Micro BC Assay 
protein Quantitation Kit, Uptima-Interchim). A total of 0.2 mg of purified re-
combinant protein was obtained from 5 × 107 Sf9 cells.  
The identity of this protein as gp51 was confirmed by Western blot analysis 
using the E4 control positive serum (Veterinary Laboratories Agency. New Haw, 
Adelestope Surrey. UK), a commercial monoclonal anti-gp51 antibody (VMRD 
Inc., WA USA) and a pool of negative control serum from BLV non-infected 
cow.  
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Figure 3. (a) Agarose gel electrophoresis of PCR product.1: DNA ladder; 2: Amplified 
894 bp PCR product. (b) SDS-PAGE analysis of recombinant gp51 protein expressed in 
Sf9insect cells. 1: Lysate from Sf9 insect cells expressing the rgp51 protein; 2: Lysate from 
non-expressing Sf9 insect cells. 
 
The Figure 4 shows that the antibodies react with a mayor band with molecu-
lar mass of approximately 34 kDa recombinant protein and several protein frac-
tions from 34 up to 50 kDa. The molecular mass of recombinant gp51 protein 
was smaller than that of the native gp51. 
3.3. Serum Control Panel Determination by AGID and ELISA  
Commercial Kit 
Of a total of 283 serum samples analyzed by AGID and commercial ELISA kits, 
were stated 101 as double positive and 109 as double negative. These serum were 
selected for further analysis, the 73 serum samples that reacted with discordant 
results between both assays were not included for the in house ELISA test.  
3.4. Characteristics Estimation of the in House ELISA Test 
The optimal concentration of recombinant proteins used as antigen for the in 
house ELISA determinate by CBT, were 250 ng per well for rp24 and 25 ng per 
well for rgp51. Three sera dilution were tested (1/25, 1/50 and 1/100) to deter-
mine the optimal performance of the assay, and the 1/25 serum dilution were 
used to perform the assay according to the best banding ratio value. The soft-
ware package Stata version 11 calculated the correct classified serum percentage 
(CC%) and the likelihood ratio for positive sera (LR+), that allow to disclosed 
the diagnostic sensibility (DSe) and specificity (DSp) of our in house ELISA test 
showed in the Table 1. 
4. Discussion 
In the epidemiological disease control of EBL it is necessary to have tests that 
increasingly sensitive, specific and be economically feasible to performed in large 
populations of animals. During the immune response against BLV the synthesis 
and persistence of specific anti-p24 and anti-gp51 antibodies is lifelong [9] [19] 
[20], this features make these two highly immunogenic proteins as candidate to 
be included in any diagnostic test for EBL. 
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Figure 4. Western Blot analysis of recombinant gp51 protein expressed 
in Sf9 insect cells. 1: Polyclonal E4 control positive sera; 2: Pool of nega-
tive control serum from BLV non-infected cow; 3: Prestained molecular 
weight marker; 4: Monoclonal anti-gp51 antibody. 
 
Table 1. Dual rp24/rgp51 ELISA assays statistical analysis by TG-ROC. Coff: cutoff; DSe: 
diagnostic sensitivity; DSp: diagnostic specificity; CC: Correct Classification. LR+: like-
lihood ratio for positive sera. 
Sera dilution Coff DSe% DSp% CC% LR+ 
1/100 0.184 86.96 86.96 86.96 6.6 
1/50 1.643 86.96 95.65 91.30 20 
1/25 0.30 95.65 91.30 93.48 9.34 
 
Firstly, in this study we successfully produced a recombinant p24 protein with 
a proved antigenicity against the control sera, the bacterial expression system 
achieved a mass production of approximately 5.6 mg per liter cultures. However, 
the production of the recombinant gp51 protein was obtaining from the baculo-
virus expression system. Although the presence and antigenicity of the recom-
binant gp51 protein in Sf9 insect cells was evident by Western blot analysis, the 
recombinant protein recognized by the monoclonal anti-gp51 antibody, showed 
the presence of several protein fractions with molecular weights ranging from 34 
kDa to about 50 kDa. All of these proteins or protein fractions that migrated 
faster than the native gp51 molecules, could represent partially glycosylated re-
combinant protein. However, the protein were anyway recognized by the posi-
tive control serum and the antigenicity maintaining its character despite incom-
plete glycosylation. Similar finding were reported in previous works by Gius-
seppe et al. [21] using the baculovirus system. From this data, we can assume 
that the heavier fraction corresponded to the band located at the height control 
molecular weight of 35 kDa, suggesting that part of the recombinant protein 
could be identified as partially glycosylated orunglycosylated product. The anti-
genic identity of the recombinant gp51 protein was confirmed also by the use of 
polyclonal control positive sera in western blot analysis. Following production 
and purification of recombinant gp51 protein in the baculovirus system, a con-
centration of 0.2 mg was obtained from 5 × 107 Sf9 cells. 
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To develop our in house ELISA test, firstly we checked the purified, optimized 
and standardized proteins asantigen by the checkerboard technique, in order to 
determine the concentration of the antigen and the sera dilution to be use in the 
test. Two independent ELISA tests for rp24 and rgp51 and also the dual ELISA 
rp24/rgp51 integrated proteins were tested. We tried different brands of 96-well 
plates and found that the 96-well plates from Nunc-Immuno Plates Polysorb 
(InterMed, Co. Denmark) were the more appropriate support to perform our in 
house ELISA test, because were where the recombinant antigens were best ad-
sorbed to the plate. Also, the antigenicity of the joined together recombinant 
proteins were kept unalterable during the development of the indirect ELISA 
test. 
From the analysis of the checkerboard results, we can concluded that a high 
BR at a concentration within the parameters suggested by R. Crowther [14], 
were obtained using a concentration of 250 ng per well of rp24 and 25 ng per 
well of rgp51. These antigen concentrations were maintained throughout all the 
tests. To perform the calculations and analysis of the results, the absorbance 
values were standardized as percentage of seropositive values. 
According to the results presented here (CCC and CV analysis) intraplate re-
peatability levels were within the values stablished by international standards 
[22]. Through the experiment, several dual rp24/rgp51 ELISA tests were per-
formed using 3 different sera dilutions (1/100, 1/50 and 1/25), in behalf of that it 
was possible to improve the performance of the test, achieving significant ad-
vances in DSe and DSp attached to the higher percentage of correct classification 
(predicted probabilities), together with a likelihood ratio of 11. 
In order to validate the results of our in house ELISA, we determine the num-
ber of samples to be processed according to the Manual of Diagnostic Tests and 
Vaccines for Terrestrial Animals Table No. IV.2 [22], where the theoretical 
number of samples from animals of known infection status required for estab-
lishing DSe and DSp estimates depending on likely value of DSe or DSp and de-
sired error margin and confidence. 
Given the sensitivity value of 95.65% obtained for the test at 1/25 dilution, we 
determined the number of samples to be processed with 5% of estimated error 
and a confidence interval of 90%. In our study, a total of 210 double positive or 
double negative sera were analyzed. The statistical analysis shows the value of 
sera correctly ranked highest (93.48%) and for 0.3 cutoff, DSe was 95.65% and 
DSp 91.30%.  
The World Organization for Animal Health (OIE) determines that the tests 
for the diagnosis of LEB are the Indirect ELISA and AGID. In our country the 
health authority accepts these two official tests, but so far there is no domestic 
production of commercial ELISA. The aim of developing a diagnostic test that 
includes together the two recombinant proteins (gp51 and p24), is to improve 
the DSe and DSp when the two proteins go together directly absorb to the 96- 
well-plate. 
Considering the prevalence of the disease and its consequences in the reduc-
tion of the productivity of livestock and indirect economic losses from the re-
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striction in international market [4] [23], it is required to developed diagnosis 
tools that increase sensitive, specific and also be economically feasible to use in 
large livestock farms. 
5. Conclusion 
In conclusion, we developed here a dual rp24/rgp51 ELISA test with two very 
promising recombinant antigens. This assay is a two-step ELISA which involves 
two binding process of primary antibody and labeled secondary antibody, with-
out using monoclonal antibodies precoating the plate. Despite a larger number 
of samples should be analyzed to validate the preliminary data obtained in this 
study; our ELISA assay has proven to be sensitive and specific, to have a good 
reproducibility, to be easy to perform, and to be suitable for screening animals 
for BLV infection. This test could be taken into account as a valid alternative to 
the AGID, not only in our country but also in others countries of South Ameri-
ca. 
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